Induced-T Cell Like NK Cellular Immunotherapy for Cancer Lack of MHC-I
Induced-T Cell Like NK Cellular Immunotherapy for Cancers That Are Lack of MHC-I Expression
Second Affiliated Hospital of Guangzhou Medical University
60 participants
Jan 1, 2019
INTERVENTIONAL
Conditions
Summary
T effector cells and NK cells have mutual compensatory killing functions on various of cancer types. For those cancers that have no available targets for CAR-T cell generations, we established potent T cell-like NK cells (ITNK) with a specific conversion protocol for the T cells from the patient, to perform anti-cancer therapy, especially for those cancers that are lack of MHC-I molecule expression. We have finished pre-clinical investigations for the ITNK or CAR-ITNK cell therapy and scheduled to start a clinical phase I study.
Eligibility
Inclusion Criteria5
- Patients with advanced cancer, which express low or no MHC-I.
- Life expectancy >12 weeks
- Adequate heart,lung,liver,kidney function
- Available autologous T cells
- Informed consent explained to, understood by and signed by patient/guardian. 6. Patient/guardian given copy of informed consent.
Exclusion Criteria9
- Had accepted gene therapy before;
- Severe virus infection such as HBV,HCV,HIV,et al
- Known HIV positivity
- History of liver or other organ transplantation
- Active infectious disease related to bacteria, virus,fungi,et al
- Other severe diseases that the investigators consider not appropriate;
- Pregnant or lactating women
- Systemic steroid treatment (greater than or equal to 0.5 mg prednisone equivalent/kg/day)
- Other conditions that the investigators consider not appropriate.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Infusion of ITNK/CAR-ITNK cells
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03882840